Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04662801 · ClinicalTrials.gov registry record · Phase 2
Weight Regain Treatment Post-Bariatric Surgery
A Phase 2 study of Obesity & Overweight, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT04662801: Completed Phase 2 study of Obesity & Overweight, sponsored by Yale University.
NCT04662801 is a Phase 2 study of Obesity & Overweight that has completed, run by Yale University. The registered enrollment target is 26 participants, below the 114-participant average among 28 other Obesity & Overweight trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04662801, a Phase 2 study of Obesity & Overweight, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine behavioral and pharmacologic (Naltrexone+Bupropion) treatments for weight regain after bariatric surgery.
Primary Outcome
BMI is calculated using measured height and weight- kg/m2.
Conditions Studied
Interventions
- BEHAVIORAL Behavioral Weight Loss (BWL)
- BEHAVIORAL Early Responder: BWL continued
- COMBINATION_PRODUCT Early Non-responder: BWL continued with medication added
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2021-08-05 |
| Est. Completion | 2022-09-13 |
| Phase | Phase 2 |
What the finished NCT04662801 record still lists
NCT04662801 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 114-participant average among 28 other Obesity & Overweight trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Obesity & Overweight appearing as the primary indexed condition, and to 3 interventions - of which Behavioral Weight Loss (BWL) is the first listed.
NCT04662801 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT04662801 about?
NCT04662801 is a clinical study titled "Weight Regain Treatment Post-Bariatric Surgery". This study will examine behavioral and pharmacologic (Naltrexone+Bupropion) treatments for weight regain after bariatric surgery.
What is the current status of trial NCT04662801?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2021-08-05. Estimated completion is 2022-09-13.
What conditions does trial NCT04662801 study?
This clinical trial studies the following conditions: Obesity & Overweight.
What interventions are being tested in trial NCT04662801?
The interventions under investigation include: Behavioral Weight Loss (BWL) (BEHAVIORAL), Early Responder: BWL continued (BEHAVIORAL), Early Non-responder: BWL continued with medication added (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04662801?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04662801 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity & Overweight
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04662801's enrollment target sits among peer trials
26 25th of 28 higher than 4 of 28 other Obesity & Overweight trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity & Overweight trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)
ACTIVE NOT RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)
ACTIVE NOT RECRUITING · Phase 2
-
Optimizing Self-Monitoring Feedback Delivery for the Treatment of Overweight and Obesity
RECRUITING · NA
-
Microrandomized Trial to Optimize Use of Burden-reducing Self-monitoring Approaches in Behavioral Obesity Treatment
RECRUITING · NA
-
Pistachio Intake and Nutrition-Related Outcomes in Individuals on GLP-1 Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI